Literature DB >> 15138953

Efficacy of accelerated dose titration of olanzapine with adjunctive lorazepam to treat acute agitation in schizophrenia.

Bruce J Kinon1, Jonna Ahl, Matthew D Rotelli, Edmund McMullen.   

Abstract

We conducted a prospective double-blind study of accelerated dose titration of olanzapine in the treatment of newly admitted acutely agitated patients with schizophrenia. Patients were randomized to either oral olanzapine (10 mg per day) or oral haloperidol (10 mg per day), plus lorazepam as needed (up to 12 mg per day). Antipsychotic dosage was increased to 20 mg per day as early as day 3. Patients were evaluated with the Positive and Negative Syndrome Scale (PANSS) Agitation subscale during the first 24 hours of treatment, daily for the first week, then weekly until study completion. Significant within-group improvement was demonstrated in PANSS Agitation scores for both groups as early as 1 hour after initiating therapy (-5.79 +/- 6.30 for olanzapine and -4.89 +/- 6.05 for haloperidol, P <.001). This study demonstrated that accelerated dose titration of oral olanzapine is as efficacious as oral haloperidol in reducing acute agitation in patients with schizophrenia.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15138953     DOI: 10.1016/j.ajem.2004.02.021

Source DB:  PubMed          Journal:  Am J Emerg Med        ISSN: 0735-6757            Impact factor:   2.469


  9 in total

Review 1.  Dose response and atypical antipsychotics in schizophrenia.

Authors:  Bruce J Kinon; Jonna Ahl; Virginia L Stauffer; Angela L Hill; Peter F Buckley
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

Review 2.  Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation).

Authors:  Edoardo G Ostinelli; Melanie J Brooke-Powney; Xue Li; Clive E Adams
Journal:  Cochrane Database Syst Rev       Date:  2017-07-31

Review 3.  'As required' medication regimens for seriously mentally ill people in hospital.

Authors:  Petrina Douglas-Hall; Emma V Whicher
Journal:  Cochrane Database Syst Rev       Date:  2015-12-21

4.  Japanese Society of Neuropsychopharmacology: "Guideline for Pharmacological Therapy of Schizophrenia".

Authors: 
Journal:  Neuropsychopharmacol Rep       Date:  2021-08-12

Review 5.  The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements.

Authors:  Robert W Buchanan; Julie Kreyenbuhl; Deanna L Kelly; Jason M Noel; Douglas L Boggs; Bernard A Fischer; Seth Himelhoch; Beverly Fang; Eunice Peterson; Patrick R Aquino; William Keller
Journal:  Schizophr Bull       Date:  2009-12-02       Impact factor: 9.306

6.  Patient perspectives on antipsychotic treatments and their association with clinical outcomes.

Authors:  Hong Liu-Seifert; Olawale O Osuntokun; Jenna L Godfrey; Peter D Feldman
Journal:  Patient Prefer Adherence       Date:  2010-10-05       Impact factor: 2.711

7.  The efficacy and safety of once-daily quetiapine extended release in patients with schizophrenia switched from other antipsychotics: an open-label study in Chinese population.

Authors:  Pei-Yin Pan; Meei-Shyuan Lee; Chin-Bin Yeh
Journal:  BMC Psychiatry       Date:  2015-01-22       Impact factor: 3.630

8.  Brazilian guidelines for the management of psychomotor agitation. Part 2. Pharmacological approach.

Authors:  Leonardo Baldaçara; Alexandre P Diaz; Verônica Leite; Lucas A Pereira; Roberto M Dos Santos; Vicente de P Gomes Júnior; Elie L B Calfat; Flávia Ismael; Cintia A M Périco; Deisy M Porto; Carlos E K Zacharias; Quirino Cordeiro; Antônio Geraldo da Silva; Teng C Tung
Journal:  Braz J Psychiatry       Date:  2019-03-07       Impact factor: 2.697

9.  Safety and effectiveness of rapid-acting intra-muscular olanzapine for agitation associated with schizophrenia - Japan postmarketing surveillance study.

Authors:  Hideaki Katagiri; Masanori Taketsuna; Shinpei Kondo; Kenta Kajimoto; Etsuko Aoi; Yuka Tanji
Journal:  Neuropsychiatr Dis Treat       Date:  2018-01-12       Impact factor: 2.570

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.